Understanding Alcohol and Cannabis Use Disorders: Insights from Dr. Kalin (2022)
Introduction Alcohol and cannabis are commonly used substances, but they can lead to serious health problems when abused. Dr. Ned […]
Ketamine for Eating Disorders: Emerging Evidence and Future Directions
Introduction Eating disorders such as anorexia nervosa and binge eating disorder are notoriously difficult to treat. In their 2022 publication
Ketamine and Eating Disorders: A New Hope for Recovery
Introduction Eating disorders like anorexia and binge eating can be tough to treat, and current therapies don’t always work for
Clinical Trial Insights: Ketamine’s Expanding Role in Psychiatry (Peyrovian et al., 2020)
Introduction: Peyrovian et al.’s 2020 review in the Journal of Psychiatric Research summarizes registered clinical trials evaluating ketamine for psychiatric
Ketamine’s Role in Mental Health Treatment: New Hope from Clinical Trials (Peyrovian et al., 2020)
Introduction: In 2020, Peyrovian and colleagues published an analysis of registered clinical trials investigating ketamine as a treatment for psychiatric
Ketamine Pilot Study for Late-Life Depression: Early Insights (Lenze, ClinicalTrials.gov, 2020)
Introduction: Dr. Eric Lenze’s 2020 pilot study investigates ketamine’s safety and efficacy in older adults with treatment-resistant depression (TRD). This
Depression, Patient Regulation
Exploring Ketamine for Older Adults: A Groundbreaking Pilot Study (Lenze, ClinicalTrials.gov, 2020)
Introduction: In 2020, Dr. Eric Lenze and his team launched a pilot study to explore how ketamine might help older
Esketamine: A Paradigm Shift in TRD Treatment (Kim et al., NEJM, 2019)
Introduction: Kim and colleagues’ 2019 article in The New England Journal of Medicine reviews the groundbreaking approval of esketamine as
Esketamine: A Groundbreaking Antidepressant Explained (Kim et al., NEJM, 2019)
Introduction: In 2019, a team of experts published an article in The New England Journal of Medicine highlighting the significance
Esketamine: Insights into a Novel NMDA Antagonist for TRD (Hough, FDA, 2019)
Introduction: Dr. David Hough’s 2019 FDA report presents a comprehensive overview of esketamine, its development, and its approval as a